791 related articles for article (PubMed ID: 7503821)
1. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
2. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S
Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
[TBL] [Abstract][Full Text] [Related]
3. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis].
von der Schulenburg JM; Greiner W; von der Hardt H
Med Klin (Munich); 1995 Apr; 90(4):220-4. PubMed ID: 7776934
[TBL] [Abstract][Full Text] [Related]
4. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
[TBL] [Abstract][Full Text] [Related]
5. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis.
Frederiksen B; Pressler T; Hansen A; Koch C; Høiby N
Acta Paediatr; 2006 Sep; 95(9):1070-4. PubMed ID: 16938752
[TBL] [Abstract][Full Text] [Related]
6. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.
Wilmott RW; Amin RS; Colin AA; DeVault A; Dozor AJ; Eigen H; Johnson C; Lester LA; McCoy K; McKean LP; Moss R; Nash ML; Jue CP; Regelmann W; Stokes DC; Fuchs HJ
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1914-7. PubMed ID: 8665055
[TBL] [Abstract][Full Text] [Related]
7. [Clinical development of rhDNase in the United States].
Eisenberg J
Arch Pediatr; 1995 Jul; 2(7):674-8. PubMed ID: 7663659
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
[TBL] [Abstract][Full Text] [Related]
9. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human DNase in children with airway malacia and lower respiratory tract infection.
Boogaard R; de Jongste JC; Vaessen-Verberne AA; Hop WC; Merkus PJ
Pediatr Pulmonol; 2009 Oct; 44(10):962-9. PubMed ID: 19768804
[TBL] [Abstract][Full Text] [Related]
12. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
Hodson ME
Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
[TBL] [Abstract][Full Text] [Related]
14. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
Suri R; Metcalfe C; Wallis C; Bush A
Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
[TBL] [Abstract][Full Text] [Related]
15. Statistical analysis of the long-term effects of recombinant human deoxyribonuclease on pulmonary function in cystic fibrosis patients.
Chen JJ; Hamilton SA
J Biopharm Stat; 2000 Aug; 10(3):287-97. PubMed ID: 10959912
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.
Suri R; Metcalfe C; Lees B; Grieve R; Flather M; Normand C; Thompson S; Bush A; Wallis C
Lancet; 2001 Oct; 358(9290):1316-21. PubMed ID: 11684212
[TBL] [Abstract][Full Text] [Related]
17. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
[TBL] [Abstract][Full Text] [Related]
18. [Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].
Hodson M
Arch Pediatr; 1995 Jul; 2(7):679-81. PubMed ID: 7663660
[TBL] [Abstract][Full Text] [Related]
19. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.
O'Donnell AE; Barker AF; Ilowite JS; Fick RB
Chest; 1998 May; 113(5):1329-34. PubMed ID: 9596315
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]